Indication
Recessive Dystrophic Epidermolysis Bullosa
8 clinical trials
5 products
Product
Beremagene GeperpavecClinical trial
Open Label Treatment of Beremagene Geperpavec (B-VEC)Status: Completed, Estimated PCD: 2023-07-31
Clinical trial
A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously "KB103") for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)Status: Completed, Estimated PCD: 2021-10-29
Clinical trial
A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Status: , Estimated PCD: 2036-02-01
Product
allo-APZ2-EBProduct
EB-101Clinical trial
An Interventional, Multicenter, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-EB on Epidermolysis Bullosa (EB)Status: Completed, Estimated PCD: 2021-11-26
Clinical trial
A Phase 2b Open-Label Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01 in Study PTR-01-002Status: Completed, Estimated PCD: 2022-06-20
Product
PTR-01Clinical trial
A Phase 3b Study for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) in New and Previously EB-101 Treated PatientsStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
VIITAL: A Phase 3 Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Status: Completed, Estimated PCD: 2022-10-18
Clinical trial
A Pilot, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-06-01
Product
Rigosertib